Wall Street brokerages expect that Aptinyx Inc (NASDAQ:APTX) will announce sales of $950,000.00 for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Aptinyx’s earnings. The lowest sales estimate is $890,000.00 and the highest is $1.00 million. Aptinyx posted sales of $2.13 million during the same quarter last year, which suggests a negative year-over-year growth rate of 55.4%. The firm is scheduled to announce its next earnings results on Tuesday, August 13th.
On average, analysts expect that Aptinyx will report full-year sales of $3.78 million for the current financial year, with estimates ranging from $3.56 million to $4.00 million. For the next fiscal year, analysts expect that the company will post sales of $2.89 million, with estimates ranging from $1.78 million to $4.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Aptinyx.
Aptinyx (NASDAQ:APTX) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.04). The firm had revenue of $0.89 million during the quarter, compared to the consensus estimate of $1.00 million. Aptinyx had a negative net margin of 1,166.40% and a negative return on equity of 37.53%.
Several analysts recently weighed in on the company. Zacks Investment Research upgraded Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a report on Tuesday. Cowen restated a “buy” rating on shares of Aptinyx in a report on Monday, June 10th. Svb Leerink assumed coverage on Aptinyx in a report on Thursday, June 20th. They issued an “outperform” rating and a $12.00 price objective for the company. BMO Capital Markets lifted their price objective on Alimentation Couche-Tard from C$79.00 to C$84.00 and gave the company an “outperform” rating in a report on Friday, March 22nd. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $143.00 price objective on shares of Eli Lilly And Co in a report on Tuesday, April 30th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $12.71.
Shares of APTX stock traded down $0.05 on Monday, hitting $3.72. The stock had a trading volume of 108,585 shares, compared to its average volume of 317,753. The business has a 50 day moving average price of $3.40. The company has a market capitalization of $126.53 million and a P/E ratio of -1.41. Aptinyx has a one year low of $2.88 and a one year high of $32.25.
In other news, Director Henry O. Gosebruch bought 100,000 shares of Aptinyx stock in a transaction on Wednesday, May 8th. The stock was acquired at an average cost of $3.86 per share, for a total transaction of $386,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 8.47% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the business. Great West Life Assurance Co. Can bought a new position in Aptinyx in the fourth quarter worth about $40,000. Partner Investment Management L.P. raised its holdings in Aptinyx by 4.6% in the fourth quarter. Partner Investment Management L.P. now owns 58,840 shares of the company’s stock worth $973,000 after purchasing an additional 2,570 shares in the last quarter. Barclays PLC raised its holdings in Aptinyx by 87.1% in the fourth quarter. Barclays PLC now owns 9,323 shares of the company’s stock worth $154,000 after purchasing an additional 4,340 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its holdings in Aptinyx by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock worth $120,000 after purchasing an additional 5,652 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in Aptinyx by 71.0% in the fourth quarter. Rhumbline Advisers now owns 16,944 shares of the company’s stock worth $280,000 after purchasing an additional 7,033 shares in the last quarter. Institutional investors and hedge funds own 58.37% of the company’s stock.
Aptinyx Company Profile
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
See Also: Insider Trading – What You Need to Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.